Status:
TERMINATED
A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
Lead Sponsor:
Janssen Research & Development, LLC
Conditions:
Dermatitis, Atopic
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of bermekimab in participants with moderate to severe atopic dermatitis (AD).
Eligibility Criteria
Inclusion
- Be otherwise healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiograms (ECGs) performed at screening. Any abnormalities, must be consistent with the underlying illness in the study population and this determination must be recorded in the participant's source documents and initialed by the investigator
- Have atopic dermatitis (AD) for at least 1 year (365 days) prior to the first administration of study intervention as determined by the investigator through participant interview and/or review of the medical history
- Have a history of inadequate response to treatment for AD with topical medications or for whom topical treatments are otherwise medically inadvisable (example \[eg\], due to important side effects or safety risks)
- Be considered, in the opinion of the investigator, a suitable candidate for dupilumab (DUPIXENT) therapy according to their country's approved DUPIXENT product labeling
- Have an eczema area and severity index (EASI) score greater than or equal (\>=) to 16 at screening and at baseline
- Have an investigator global assessment (IGA) score \>=3 and involved body surface area (BSA) \>=10 percent (%) at screening and baseline
Exclusion
- Has a current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- Has unstable cardiovascular disease, defined as a recent clinical deterioration (eg, unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months
- Has or has had a serious infection (eg, sepsis, pneumonia, or pyelonephritis), or has been hospitalized or received intravenous (IV) antibiotics for an infection during the 2 months before screening
- Has or has had herpes zoster within the 2 months before screening
- Has a history of being human immunodeficiency virus (HIV) antibody-positive, or tests positive for HIV at screening
Key Trial Info
Start Date :
May 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2022
Estimated Enrollment :
199 Patients enrolled
Trial Details
Trial ID
NCT04791319
Start Date
May 3 2021
End Date
March 31 2022
Last Update
March 1 2023
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
California Allergy & Asthma Medical Group Inc.
Los Angeles, California, United States, 90025
2
Wolverine Clinical Trials
Santa Ana, California, United States, 92705
3
Park Avenue Dermatology
Orange Park, Florida, United States, 32073
4
Forcare Clinical Research, Inc.
Tampa, Florida, United States, 33613